We are committed to translating ground-breaking science into genomic therapies that transform patients’ lives.

Passionate. Guided by Science. Results Oriented.

Sangamo was founded in 1995 as Sangamo BioSciences, Inc. in order to research new technologies for genome editing. Over two decades, Sangamo's scientists developed the most advanced, flexible and precise technologies available for gene-based therapies. In 2017, Sangamo is conducting new human clinical trials, including the first ever in vivo human genome editing studies. Reflecting this focus on the clinical development of new genomic therapies, in 2017 the Company announced a new name, Sangamo Therapeutics.

For Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. The Company's scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. Sangamo expects its scientific investment will reliably generate new programs for human clinical development.

Passionate. Guided by Science. Results Oriented.

We Persevere When the Goal is Audacious

Our highest priority is to meet the needs of patients with commitment and compassion.

We strive to be transparent and trustworthy, while taking a strategic and focused approach to our work translating cutting-edge science into new medicines for genetic diseases. We are passionate about what we do and having fun while we do it.  We seek to create an inclusive family of science and business professionals striving for success.

Backed by years of expertise

We have assembled an experienced team to develop genomic therapies for rare diseases across all the necessary competencies: regulatory, manufacturing, technical operations, clinical development and commercial strategy.

View Leadership